CVRx (CVRX) Stock Price, News & Analysis

Company Overview

CVRx, Inc. is a medical device company that develops and commercializes neuromodulation therapies for patients with cardiovascular diseases. The company’s technology is designed to use the body’s nervous system to help regulate cardiovascular function and address conditions that may not be adequately managed with conventional drug therapy.

CVRx’s primary product is Barostim, an implantable system that electrically stimulates the baroreceptors located near the carotid arteries. The therapy is intended to activate the body’s natural cardiovascular regulation mechanisms and is used primarily in eligible patients with heart failure, including certain patients with reduced ejection fraction. Barostim has received regulatory clearance in the United States and is marketed in selected international markets.

Founded in 2001 and headquartered in Minneapolis, Minnesota, CVRx sells its products through a combination of direct commercial operations and distribution relationships. The company focuses on expanding adoption of Barostim among physicians and hospitals while continuing to develop therapies based on neuromodulation for cardiovascular conditions.

Key Stats

• Today's Range: $1.51 to $1.62
• 50-Day Range: $1.53 to $5.94
• 52-Week Range: $1.50 to $11.30
• Volume: 576,646 shs
• Average Volume: 528,620 shs
• Market Capitalization: $41.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.30
• Consensus Rating: Hold

CVRx Stock Analysis - MarketRank™

CVRx scored higher than 77% of companies evaluated by MarketBeat, and ranked 131st out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

CVRx has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no strong buy ratings, 2 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

CVRx has a consensus price target of $4.30, representing about 175.6% upside from its current price of $1.56.

Amount of Analyst Coverage

CVRx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CVRx are expected to grow in the coming year, from ($2.00) to ($1.91) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CVRx is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CVRx is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CVRx has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.40% of the float of CVRx has been sold short.

Short Interest Ratio / Days to Cover

CVRx has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CVRx has recently decreased by 16.50%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CVRx does not currently pay a dividend.

Dividend Growth

CVRx does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for CVRx this week, compared to 4 articles on an average week.

Search Interest

1 people have searched for CVRX on MarketBeat in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $72,971.00 in company stock, which represents 0.1756% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, CVRx insiders have bought 2,186.07% more of their company's stock than they have sold. Specifically, they have bought $76,309.00 in company stock and sold $3,338.00 in company stock.

Percentage Held by Insiders

16.60% of the stock of CVRx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.27% of the stock of CVRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:CVRX
• CIK: 1235912
• Web: www.cvrx.com
• Phone: (763) 416-2850
• Fax: 763-416-2841
• Employees: 223
• Year Founded: 2001

Price Target and Rating

• Average Price Target for CVRx: $4.30
• High Price Target: $5.00
• Low Price Target: $3.50
• Potential Upside/Downside: +175.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$53.31 million
• Net Margins: -84.93%
• Pretax Margin: -84.94%
• Return on Equity: -152.35%
• Return on Assets: -50.93%

Debt

• Debt-to-Equity Ratio: 2.94
• Current Ratio: 8.04
• Quick Ratio: 6.87

Sales & Book Value

• Annual Sales: $56.65 million
• Price / Sales: 0.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.50 per share
• Price / Book: 1.04

Miscellaneous

• Outstanding Shares: 26,640,000
• Free Float: 22,219,000
• Market Cap: $41.56 million
• Optionable: Optionable
• Beta: 0.77